

Subject index of volume 22

Antibody 81
 - leukocyte dependent cytotoxicity 221
 - monoclonal 1, 139
 - tumor localization 139, 169
 Antigen
 - HLA class II 232
 - prostate cancer 1
 Autoradiography
 - tumor 139

BCG 87, 155, 204
 Biological response modifier 8
 Blastogenesis 107
 Bovine ocular squamous cell carcinoma 87
 Breast cancer 72, 76, 139

Cervical cancer 76
 Colon cancer 139, 217
 Concanavalin A 43
Corynebacterium parvum 49, 56

Daunorubicin 81
 Delayed type hypersensitivity 114

Epstein Barr virus 62

5-Fluorouracil 43

Gastric carcinoma 148

Immune complexes 72
 Immune reactivity
 - cattle 87
 Immune response
 - antitumor 43
 Immunochemotherapy 3, 81, 148
 Immunoglobulins 76
 Immunotherapy 49, 68, 181, 197
 Interferon 114, 144, 211, 217
 Interleukin 2 31, 49
 Interleukin 3 49

Leukemia 95
 Leukocyte
 - dependent antibody activity 221
 Liposomes 191
 Lung cancer 56, 155, 211, 232

Lymphocyte
 - activated killer cells 161
 - B 62
 - cytotoxic T 15, 31, 107, 161
 - HLA class II antigens 232
 - immunity 114
 - recruitment 37
 - suppressor 43
 Lymphoma
 - SL2 100

Macrophage 100, 125, 132, 186, 197
 - activating factor (MAF) 132
 Melanoma 15, 72, 197
 - vaccinia cell lysates 221
 Melphalan 43
 Metastasis 181
 Monocytes 144, 176, 191
 Muramyl tripeptide 191
 MVE 68

NK cells 161
Nocardia rubra cell wall skeleton (N-CWS) 132, 148

OK-432 161
 Oral cancer 76

Propionibacterium acnes 24
 Prostaglandin E 37
 Prostate cancer 1
 PS-K 114, 181

Squamous cell carcinoma
 - bovine ocular 87

Tumor
 - adherent cells 125
 - associated macrophages 186
 - BCG cell mixtures 204
 - cells xenogenized 204
 - clonogenic cells 186
 - immunity 8, 100
 - immunogenicity 119, 204

Vaccinia virus 197

Yolk sac tumor 81

- Wallace RE, see Wang BS, et al. 8
- Wang BS, Ruszala-Mallon V, Wallace RE, Citarella RV, Lin Y, Durr
FE: Modulation of the immune response to tumors by a novel
synthetic compound, N-[4-[(4-fluorophenyl)sulfonyl]phenyl]
acetamide (CL 259,763) 8
- Watanabe A, see Koyama S, et al. 148
- White ChP, see Hamburger AW 186
- Wiltout RH, see Salup RR 31
- Xu Z, see Hosokawa M, et al. 181
- Yamamura Y, see Masuno T, et al. 132
- Yokoyama K, see Koyama S, et al. 148
- Zinnaka Y, see Tsuru S, et al. 114



Contents of volume 22

- Ankathil R, see Vijayakumar T, et al. 76
- Ashman LK, O'Keefe DE, Juttner CA, Toogood IRG, Rice MS: Autologous responses to human leukaemic cells in mixed leucocyte culture 95
- Atkinson B, see Lindgren J, et al. 1
- Austgulen R, Kildahl-Andersen O, Espevik T: Monocyte-mediated drug-dependent cellular cytotoxicity: effects on different WEHI 164 target cell lines 176
- Bakker W, Nijhuis-Heddes JMA, van der Velde EA: Post-operative intrapleural BCG in lung cancer: A 5-year follow-up report 155
- Ball ED, Nichols KE, Pettengill OS, Sorenson GD, Fanger MW: Lysis of small cell carcinoma of the lung tumor cell lines by gamma interferon-activated allogeneic peripheral blood mononuclear cells: abrogation of killing by pretreatment of tumor cells with gamma interferon 211
- Berek J, see Lichtenstein A 24
- Ben-Efraim S, Shoval S, Ophir R: The difference between 5-fluorouracil and melphalan in their ability to promote antitumor immune response against MOPC-315 plasmacytoma 43
- Blaszczak M, see Lindgren J, et al. 1
- Blazar BA, Sutton LM, Strome M: Immunomodulating activity in supernatants from EBV immortalized lymphocytes 62
- Bucana C, see Saiki I, et al. 125
- Burns C, see Hersey P, et al. 15
- Byrne JA, see Natuk RJ, et al. 197
- Citarella RV, see Wang BS, et al. 8
- D'Alessandro G, see Hersey P, et al. 221
- de Bruin RWF, see Eggermont AMM, et al. 217
- de Jong WH, see Klein WR, et al. 87
- Den Otter W, see Dullens HFJ, et al. 100
- Dullens HFJ, Schakenraad S, Oostdijk A, Vuist W, van der Maas M, Den Otter W: Specific tumoricidal activity of cytotoxic macrophages and cytotoxic lymphocytes 100
- Durr FE, see Wang BS, et al. 8
- Edwards A, see Hersey P, et al. 221
- Eggermont AMM, Marquet RL, de Bruin RWF, Jeekel J: Effects of the interferon-inducer ABPP on colon cancer in rats; importance of tumor load and tumor site 217
- Elgert KD, see Roberson AM 49
- Ernst P, see Nielsen H 144
- Espevik T, see Austgulen R, et al. 176
- Fanger MW, see Ball ED, et al. 211
- Ferrone S, see Indiveri F, et al. 232
- Fidler IJ, see Saiki I, et al. 125
- Forbes JT, see Hainsworth JD, et al. 68
- Fujisawa H, see Tsuru S, et al. 114
- Gallagher BM, see Jones PL, et al. 139
- Gallagher BM, see Sands H, et al. 169
- Greco FA, see Hainsworth JD, et al. 68
- Grosh WW, see Hainsworth JD, et al. 68
- Hainsworth JD, Forbes JT, Grosh WW, Greco FA: Phase I study of MVE-2 evaluating toxicity and biologic response modification capability 68
- Hamburger AW, White ChP: Growth factors for human tumor clonogenic cells elaborated by macrophages isolated from human malignant effusions 186
- Hayashi S, see Masuno T, et al. 132
- Hersey P, MacDonald M, Schibeci S, Burns C: Clonal analysis of cytotoxic T lymphocytes (CTL) against autologous melanoma. Classification based on phenotype, specificity and inhibition by monoclonal antibodies to T cell structures 15
- Hersey P, Edwards A, D'Alessandro G, MacDonald M: Phase II study of vaccinia melanoma cell lysates (VMCL) as adjuvant to surgical treatment of stage II melanoma; II. Effects on cell mediated cytotoxicity and leucocyte dependent antibody activity: Immunological effects of VMCL in melanoma patients 221
- Hibi N, see Ohkawa K, et al. 81
- Holowczak JA, see Natuk RJ, et al. 197
- Hosokawa M, Mizukoshi T, Morikawa K, Xu Z, Kobayashi H: The therapeutic effects of an immunopotentiator, PS-K, on 3-methylcholanthrene-induced autochthonous tumors in C57BL/6 mice in combination with the surgical removal of primary sites 181
- Hosokawa M, see Suzuki Y, et al. 204
- Hvid-Hansen H, see Kaufmann M, et al. 56
- Ichimura O, see Saito M, et al. 161
- Ikedo T, see Masuno T, et al. 132
- Indiveri F, Pierri I, Rognà S, Poggi A, Romano R, Tavano A, Ratto G, Motta G, Ferrone S: Abnormalities of T cells isolated from mediastinal lymph nodes and peripheral blood of patients with lung carcinoma: deficit in PHA-induced expression of HLA Class II antigens and in autologous mixed lymphocyte reactions 232
- Ishida N, see Saito M, et al. 161
- Ito M, see Masuno T, et al. 132
- Iwasaki Y, see Koyama S, et al. 148
- Jeekel J, see Eggermont AMM, et al. 217
- Jones PL, Gallagher BM, Sands H: Autoradiographic analysis of monoclonal antibody distribution in human colon and breast tumor xenografts 139
- Jones PL, see Sands H, et al. 169
- Juttner CA, see Ashman LK, et al. 95
- Kamikaseda K, see Tanaka K, et al. 37
- Kataoka M, see Saito M, et al. 161
- Kaufmann M, Marqverson J, Stanley KE, Mouritzen C, Hvid-Hansen: Distribution of intrapleural and intravenous *Corynebacterium parvum* in humans; ^{99m}Tc- and ¹³¹I-labeled bacteria 56
- Kawasaki T, see Koyama S, et al. 148
- Kildahl-Andersen O, see Austgulen R, et al. 176
- Kishimoto S, see Masuno T, et al. 132
- Klein WR, Steerenberg PA, Poelma F, Wiel E v. d., Rutten VPMG, Misdorp W, de Jong WH, Ruitenberg EJ: Immune reactivity in cattle with ocular squamous cell-carcinoma after intralésional BCG immunotherapy 87
- Kobayashi H, see Hosokawa M, et al. 181
- Kobayashi H, see Suzuki Y, et al. 204
- Koga Y, see Tanaka K, et al. 37
- Koizumi S, see Koyama S, et al. 148
- Koprowski H, see Lindgren J, et al. 1
- Koyama S, Ozaki A, Iwasaki Y, Sakita T, Osuga T, Watanabe A, Suzuki M, Kawasaki T, Soma T, Tabuchi T, Nakayama M, Koizumi S, Yokoyama K, Uchida T, Orii K, Tanaka T: Randomized controlled study of postoperative adjuvant immunotherapy with *Nocardia rubra* cell wall skeleton (N-CWS) and Tegafur for gastric carcinoma 148
- Lichtenstein A, Berek J: Antitumor and immunologic effects of a pyridine-extracted fraction of *Propionibacterium acnes* 24
- Lin Y, see Wang BS, et al. 8
- Lindgren J, Blaszczak M, Atkinson B, Steplewski Z, Koprowski H: Monoclonal antibody-defined antigens of human prostate cancer cell line PC3 1

- MacDonald M, see Hersey P, et al. 15
- MacDonald M, see Hersey P, et al. 221
- Marquet RL, see Eggermont AMM, et al. 217
- Marqverson J, see Kaufmann M, et al. 56
- Masuno T, Hayashi S, Ito M, Ikeda T, Ogura T, Kishimoto S, Yama-mura Y. Mechanism(s) of in vitro macrophage activation with *Nocardia rubra* cell wall skeleton: the effects on macrophage activating factor production by lymphocytes 132
- Misdorp W, see Klein WR, et al. 87
- Mizukoshi T, see Hosokawa M, et al. 181
- Moore M, see Roberts TE, et al. 107
- Morikawa K, see Hosokawa M, et al. 181
- Moriya Y, see Saito M, et al. 161
- Motta G, see Indiveri F, et al. 232
- Mouritzen C, see Kaufmann M, et al. 56
- Nakayama M, see Koyama S, et al. 148
- Nanjo M, see Saito M, et al. 161
- Natuk RJ, Byrne JA, Holowczak JA: Infection of DBA/2 or C3H/HeJ mice by intraperitoneal injection of vaccinia virus elicits activated macrophages, cytolytic and cytostatic for S91-melanoma tumor cells 197
- Nayar R, see Saiki I, et al. 125
- Neacy WP, see Sands H, et al. 169
- Nichols KE, see Ball ED, et al. 211
- Nielsen H, Ernst P: Enhancement of defective monocyte function during immunotherapy with recombinant interferon 144
- Nijhuis-Heddes JMA, see Bakker W, et al. 155
- Nomoto K, see Tanaka K, et al. 37
- Nomoto K, see Tsuru S, et al. 114
- Ogawara M, see Sone S, et al. 191
- Ogura T, see Masuno T, et al. 132
- Ohkawa K, Hibi N, Tsukada Y: Evaluation of a conjugate of purified antibodies against human AFP-dextran-daunorubicin to human AFP-producing yolk sac tumor cell lines 81
- O'Keefe DE, see Ashman LK, et al. 95
- Oostdijk A, see Dullens HFJ, et al. 100
- Ophir R, see Ben-Efraim S, et al. 43
- Or A, see Richert L, et al. 119
- Orii K, see Koyama S, et al. 148
- Osuga T, see Koyama S, et al. 148
- Ozaki A, see Koyama S, et al. 148
- Pettengill OS, see Ball ED, et al. 211
- Pierrri I, see Indiveri F, et al. 232
- Poelma F, see Klein WR, et al. 87
- Poggi A, see Indiveri F, et al. 232
- Ratto G, see Indiveri F, et al. 232
- Remani P, see Vijayakumar T, et al. 76
- Rice MS, see Ashman LK, et al. 95
- Richert L, Or A, Shinitzky M: Promotion of tumor antigenicity in EL-4 leukemia cells by hydrostatic pressure 119
- Roberson AM, Elgert KD: Splenocytes from tumor-bearing *Corynebacterium parvum* treated mice maintain interleukin-2 and -3 activity 49
- Roberts TE, Shipton U, Moore M: Proliferative and cytotoxic responses of human peripheral blood lymphocytes to autologous malignant effusions. An analysis at the clonal level 107
- Rogna S, see Indiveri F, et al. 232
- Romano R, see Indiveri F, et al. 232
- Ronai Z, Shaham J, Stein J, Sulitzeanu: Serial circulating immune complex values and development of metastatic disease in breast cancer and malignant melanoma patients 72
- Ruitenber EJ, see Klein WR, et al. 87
- Ruszala-Mallon V, see Wang BS, et al. 8
- Rutten VPMG, see Klein WR, et al. 87
- Saiki I, Nayar R, Bucana C, Fidler IJ: A microassay for the rapid and selective binding of cells from solid tumors to mouse macrophages 125
- Saito M, Ichimura O, Kataoka M, Moriya Y, Ueno K, Sugawara Y, Nanjo M, Ishida N: Pronounced antitumor effect of LAK-like cells induced in the peritoneal cavity of mice after intraperitoneal injection of OK-432, a killed *Streptococcal* preparation 161
- Sakita T, see Koyama S, et al. 148
- Salup RR, Wiltout RH: Treatment of adenocarcinoma in the peritoneum of mice: Chemoinmunotherapy with IL-2-stimulated cytotoxic lymphocytes as a model for treatment of minimal residual disease 31
- Sands H, see Jones PL, et al. 139
- Sands H, Jones PL, Neacy WP, Shah SA, Gallagher BM: Site-related differences in the localization of the monoclonal antibody OX7 in SL2 and SL1 lymphomas 169
- Sasidharan VK, see Vijayakumar T, et al. 76
- Schakenraad S, see Dullens HFJ, et al. 100
- Schibeci S, see Hersey P, et al. 15
- Shah SA, see Sands H, et al. 169
- Shaham J, see Ronai Z, et al. 72
- Shinitzky M, see Richert L, et al. 119
- Shipton U, see Roberts TE, et al. 107
- Shoval S, see Ben-Efraim S, et al. 43
- Soma T, see Koyama S, et al. 148
- Sone S, Utsugi T, Tandon P, Ogawara M: A dried preparation of liposomes containing muramyl tripeptide phosphatidylethanolamine as a potent activator of human blood monocytes to the antitumor state 191
- Sorenson GD, see Ball ED, et al. 211
- Stanley KE, see Kaufmann M, et al. 56
- Steenenber PA, see Klein WR, et al. 87
- Stein J, see Ronai Z, et al. 72
- Steplewski Z, see Lindgren J, et al. 1
- Strome M, see Blazar BA, et al. 62
- Sugawara Y, see Saito M, et al. 161
- Sulitzeanu D, see Ronai Z, et al. 72
- Sutton LM, see Blazar BA, et al. 62
- Suzuki M, see Koyama S, et al. 148
- Suzuki K, see Suzuki Y, et al. 204
- Suzuki Y, Suzuki K, Hosokawa M, Kobayashi H: Immunogenicity of viable tumor cells: A comparison of xenogenized tumor cells and BCG-tumor cell mixtures 204
- Tabuchi T, see Koyama S, et al. 148
- Tanaka K, Koga Y, Taniguchi K, Kamikaseda K, Nomoto K: T cell recruitment from the thymus to the spleen in tumor-bearing mice. I. Analysis of recruited cells by surface markers 37
- Tanaka T, see Koyama S, et al. 148
- Tandon P, see Sone S, et al. 191
- Taniguchi K, see Tanaka K, et al. 37
- Taniguchi M, see Tsuru S, et al. 114
- Tavano A, see Indiveri F, et al. 232
- Toogood IRG, see Ashman LK, et al. 95
- Tsukada Y, see Ohkawa K, et al. 81
- Tsuru S, Nomoto K, Taniguchi M, Fujisawa H, Zinnaka Y: Depression of protective mechanism during the early phase of a viral infection in tumor-bearing mice and prevention by PSK 114
- Uchida T, see Koyama S, et al. 148
- Ueno K, see Saito M, et al. 161
- Utsugi T, see Sone S, et al. 191
- van der Maas M, see Dullens HFJ, et al. 100
- van der Velde EA, see Bakker W, et al. 155
- van der Wiel E, see Klein WR, et al. 87
- Vasudevan DM, see Vijayakumar T, et al. 76
- Vijayakumar T, Ankathil R, Remani P, Sasidharan VK, Vijayan KK, Vasudevan DM: Serum immunoglobulins in patients with carcinoma of the oral cavity, uterine cervix and breast 76
- Vijayan KK, see Vijayakumar T, et al. 76
- Vuist W, see Dullens HFJ, et al. 100

